Current Issue

Model could help select initial glucose-lowering therapy for type 2 diabetes

Age, duration of diabetes, sex, baseline body mass index, and baseline levels of HbA1c, estimated glomerular filtration rate, cholesterol levels, and alanine aminotransferase were used to predict the effectiveness of five classes of diabetes drugs.

One-hour glucose tolerance test accurate, convenient for postpartum assessment

The one-hour test identified dysglycemia in 60 of 70 patients who were also diagnosed by their two-hour glucose value, as well as 96 additional patients, a single-center Canadian study found.

Studies show potential sequelae on diabetic eye from cataract surgery, GLP-1 use

One retrospective study found that progression to proliferative diabetic retinopathy was more likely after cataract surgery, while another showed that a modest increase in the risk of nonarteritic anterior ischemic optic neuropathy may be associated with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide.

MKSAP quiz: Follow-up of gestational diabetes

This month's quiz asks readers to evaluate a 27-year-old woman who was diagnosed with gestational diabetes and is now six weeks postpartum from an uncomplicated vaginal delivery.

Spotlight on SGLT-2 inhibitors and DKA

Recent studies measured rates of diabetic ketoacidosis (DKA) in patients taking sodium-glucose cotransporter-2 (SGLT-2) inhibitors by looking at hospital records, emergency surgery outcomes, and a clinic specializing in ketogenic diets.

Depression risk lower with GLP-1 receptor agonists than DPP-4 inhibitors, target trial finds

Older patients with type 2 diabetes taking glucagon-like peptide-1 (GLP-1) receptor agonists had a modestly decreased risk for incident depression compared with those on dipeptidyl peptidase-4 (DPP-4) inhibitors, but no difference was found compared to sodium-glucose cotransporter-2 inhibitors, according to the target trial emulation study.

Semaglutide-induced skin burning

A recent case report described an unusual adverse drug event in a patient with prediabetes.

Approvals for biosimilar, CGM software

The FDA approved a biosimilar insulin and expanded its approval of an interoperable automated glycemic controller for use with continuous glucose monitors (CGMs) in recent weeks.